Caliway Biopharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Caliway Biopharmaceuticals has a total shareholder equity of NT$9.7B and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$9.8B and NT$70.2M respectively.
Key information
0%
Debt to equity ratio
NT$0
Debt
| Interest coverage ratio | n/a |
| Cash | NT$9.69b |
| Equity | NT$9.73b |
| Total liabilities | NT$70.23m |
| Total assets | NT$9.80b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 6919's short term assets (NT$9.7B) exceed its short term liabilities (NT$65.0M).
Long Term Liabilities: 6919's short term assets (NT$9.7B) exceed its long term liabilities (NT$5.2M).
Debt to Equity History and Analysis
Debt Level: 6919 is debt free.
Reducing Debt: 6919 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6919 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 6919 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.